To this end, humanized mice were infected with EBV and 1 wk later with X4-tropic HIV-1, followed by treatment with either CD8+ T-cell–depleting antibody or PBS at week 2 and 4 post-EBV infection (Fig 4D). This evidence concerns the gene CD8A and Epstein-Barr virus infection.